158 related articles for article (PubMed ID: 12922084)
1. Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D.
Domingo C; Gadea I; Pardeiro M; Castilla C; Fernández S; Fernández-Clua MA; De la Cruz Troca JJ; Punzón C; Soriano F; Fresno M; Tabarés E
Vaccine; 2003 Sep; 21(25-26):3565-74. PubMed ID: 12922084
[TBL] [Abstract][Full Text] [Related]
2. Co-immunization with plasmids coding the full length and a soluble form of glycoprotein D of HSV-2 induces protective cellular and humoral immune response in mice.
Fló J
Vaccine; 2003 Mar; 21(11-12):1239-45. PubMed ID: 12559804
[TBL] [Abstract][Full Text] [Related]
3. Immunization with HSV-2 gB-CCL19 Fusion Constructs Protects Mice against Lethal Vaginal Challenge.
Yan Y; Hu K; Deng X; Guan X; Luo S; Tong L; Du T; Fu M; Zhang M; Liu Y; Hu Q
J Immunol; 2015 Jul; 195(1):329-38. PubMed ID: 25994965
[TBL] [Abstract][Full Text] [Related]
4. CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge.
Yan Y; Hu K; Fu M; Deng X; Luo S; Tong L; Guan X; He S; Li C; Jin W; Du T; Zheng Z; Zhang M; Liu Y; Hu Q
mSphere; 2021 Apr; 6(2):. PubMed ID: 33910988
[TBL] [Abstract][Full Text] [Related]
5. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.
Kuklin N; Daheshia M; Karem K; Manickan E; Rouse BT
J Virol; 1997 Apr; 71(4):3138-45. PubMed ID: 9060677
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
[TBL] [Abstract][Full Text] [Related]
7. The application of a plasmid DNA encoding IFN-alpha 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice.
Härle P; Noisakran S; Carr DJ
J Immunol; 2001 Feb; 166(3):1803-12. PubMed ID: 11160227
[TBL] [Abstract][Full Text] [Related]
8. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs.
McClements WL; Armstrong ME; Keys RD; Liu MA
Vaccine; 1997 Jun; 15(8):857-60. PubMed ID: 9234533
[TBL] [Abstract][Full Text] [Related]
9. Antibody-inducing properties of a prototype bivalent herpes simplex virus/enterotoxigenic Escherichia coli DNA vaccine.
Lásaro MO; Alves AM; Botosso VF; Durigon EL; Ferreira LC
FEMS Immunol Med Microbiol; 2003 Jan; 35(1):25-31. PubMed ID: 12589954
[TBL] [Abstract][Full Text] [Related]
10. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B
PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438
[TBL] [Abstract][Full Text] [Related]
11. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
[TBL] [Abstract][Full Text] [Related]
12. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
13. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.
Natuk RJ; Cooper D; Guo M; Calderon P; Wright KJ; Nasar F; Witko S; Pawlyk D; Lee M; DeStefano J; Tummolo D; Abramovitz AS; Gangolli S; Kalyan N; Clarke DK; Hendry RM; Eldridge JH; Udem SA; Kowalski J
J Virol; 2006 May; 80(9):4447-57. PubMed ID: 16611905
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
[TBL] [Abstract][Full Text] [Related]
16. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.
Görander S; Harandi AM; Lindqvist M; Bergström T; Liljeqvist JÅ
J Virol; 2012 Jul; 86(14):7544-53. PubMed ID: 22553328
[TBL] [Abstract][Full Text] [Related]
17. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.
Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG
J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742
[TBL] [Abstract][Full Text] [Related]
18. Optimized DNA Vaccine Enhanced by Adjuvant IL28B Induces Protective Immune Responses Against Herpes Simplex Virus Type 2 in Mice.
Zhou Y; Wang Z; Xu Y; Zhang Z; Hua R; Liu W; Jiang C; Chen Y; Yang W; Kong W
Viral Immunol; 2017 Oct; 30(8):601-614. PubMed ID: 28650722
[TBL] [Abstract][Full Text] [Related]
19. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
20. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.
Bourne N; Milligan GN; Schleiss MR; Bernstein DI; Stanberry LR
Vaccine; 1996 Sep; 14(13):1230-4. PubMed ID: 8961510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
